Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.210
Sell
RSI(14)
42.025
Neutral
STOCH(KDJ)(9,3,3)
21.406
Sell
ATR(14)
1.695
Low Volatility
CCI(14)
-110.200
Sell
Williams %R
90.281
Oversold
TRIX(12,20)
-0.354
Sell
StochRSI(14)
0.000
Oversold
STAAR Surgical Co
STAA23.350USD
-0.280-1.18%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.15BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of STAAR Surgical Co
Currency: USD Updated: 2025-12-26Key Insights
STAAR Surgical Co's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 52/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 24.97.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
STAAR Surgical Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Hold
Current Rating
24.969
Target Price
+6.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
STAAR Surgical Co Highlights
StrengthsRisks
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -11.96, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 49.83M shares, decreasing 23.09% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.26M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.61.
Financial Health
Currency: USD Updated: 2025-12-26The current financial score of STAAR Surgical Co is 8.32, ranking 45/207 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 94.73M, representing a year-over-year increase of 6.93%, while its net profit experienced a year-over-year increase of 10.98%.
Score
Financials
9.86
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.61
Operational Efficiency
6.91
Growth Potential
9.82
Shareholder Returns
7.39
STAAR Surgical Co's Company Valuation
Currency: USD Updated: 2025-12-26The current valuation score of STAAR Surgical Co is 7.22, ranking 113/207 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -11.96, which is -1484.73% below the recent high of 165.61 and -407.95% above the recent low of -60.75.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 52/207
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-26The current earnings forecast score of STAAR Surgical Co is 6.00, ranking 174/207 in the Healthcare Equipment & Supplies industry. The average price target for STAAR Surgical Co is 28.00, with a high of 30.75 and a low of 16.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
9
analysts
Hold
Current Rating
24.969
Target Price
+6.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
112
Total
6
Median
9
Average
Company name
Ratings
Analysts
STAAR Surgical Co
STAA
9
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-26The current price momentum score of STAAR Surgical Co is 5.96, ranking 163/207 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 26.29 and the support level at 21.66, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
24.050
Sell
MA10
24.265
Sell
MA20
24.848
Sell
MA50
25.701
Sell
MA100
26.511
Sell
MA200
22.144
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-26The current institutional shareholding score of STAAR Surgical Co is 10.00, ranking 1/207 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 100.45%, representing a quarter-over-quarter decrease of 8.33%. The largest institutional shareholder is The Vanguard, holding a total of 4.26M shares, representing 8.56% of shares outstanding, with 21.55% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Broadwood Capital, Inc.
BlackRock Institutional Trust Company, N.A.
Yunqi Capital Limited
State Street Investment Management (US)
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-26The current risk assessment score of STAAR Surgical Co is 7.31, ranking 37/207 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
1.00
VaR
+5.51%
240-Day Maximum Drawdown
+39.62%
240-Day Volatility
+81.63%
Return
Best Daily Return
60 days
+8.27%
120 days
+46.13%
5 years
+46.13%
Worst Daily Return
60 days
-7.25%
120 days
-7.25%
5 years
-24.68%
Sharpe Ratio
60 days
-0.74
120 days
+1.22
5 years
-0.16
Risk Assessment
Maximum Drawdown
240 days
+39.62%
3 years
+79.28%
5 years
+90.72%
Return-to-Drawdown Ratio
240 days
+0.10
3 years
-0.28
5 years
-0.16
Skewness
240 days
+3.53
3 years
+2.11
5 years
+1.33
Volatility
Realised Volatility
240 days
+81.63%
5 years
+64.79%
Standardised True Range
240 days
+4.44%
5 years
+13.12%
Downside Risk-Adjusted Return
120 days
+321.82%
240 days
+321.82%
Maximum Daily Upside Volatility
60 days
+48.70%
Maximum Daily Downside Volatility
60 days
+45.34%
Liquidity
Average Turnover Rate
60 days
+3.24%
120 days
+2.56%
5 years
--
Turnover Deviation
20 days
+261.25%
60 days
+77.73%
120 days
+40.56%
Peer Comparison
Healthcare Equipment & Supplies
STAAR Surgical Co
STAA
7.29 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of STAAR Surgical Co?
The TradingKey Stock Score provides a comprehensive assessment of STAAR Surgical Co based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of STAAR Surgical Co’s performance and outlook.
How do we generate the financial health score of STAAR Surgical Co?
To generate the financial health score of STAAR Surgical Co, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects STAAR Surgical Co's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of STAAR Surgical Co.
How do we generate the company valuation score of STAAR Surgical Co?
To generate the company valuation score of STAAR Surgical Co, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare STAAR Surgical Co’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of STAAR Surgical Co’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of STAAR Surgical Co.
How do we generate the earnings forecast score of STAAR Surgical Co?
To calculate the earnings forecast score of STAAR Surgical Co, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on STAAR Surgical Co’s future.
How do we generate the price momentum score of STAAR Surgical Co?
When generating the price momentum score for STAAR Surgical Co, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of STAAR Surgical Co’s prices. A higher score indicates a more stable short-term price trend for STAAR Surgical Co.
How do we generate the institutional confidence score of STAAR Surgical Co?
To generate the institutional confidence score of STAAR Surgical Co, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about STAAR Surgical Co’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of STAAR Surgical Co.
How do we generate the risk management score of STAAR Surgical Co?
To assess the risk management score of STAAR Surgical Co, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of STAAR Surgical Co’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of STAAR Surgical Co.
